The global RNA based therapeutic market size is calculated at USD 9.46 billion in 2025 and is expected to reach around USD 40 ...

A high-quality genome assembly of Silene latifolia was generated by researchers at CNRS/Université Claude Bernard Lyon 1 and ...

WVE-007 is a novel, long-acting GalNAc-siRNA targeting INHBE mRNA – a genetically validated target that provides a new ...

Arrowhead Pharmaceuticals recently received the FDA NDA acceptance for Plozasiran. Read why I believe ARWR stock could be a ...

Elsewhere, cell therapy developer Turnstone Biologics announced a second round of layoffs and plans to explore “strategic alternatives.” ...

WVE-007 is a novel, long-acting GalNAc-siRNA targeting INHBE mRNA - a genetically validated target that provides a new approach for healthy, sustainable weight loss (fat loss with muscle preservation) ...

GreenLight Biosciences España, a biotechnology company pioneering RNA-based solutions for agriculture, announced that it has received a €35M loan from the ...

Fintel reports that on February 11, 2025, Goldman Sachs initiated coverage of Silence Therapeutics plc - Depositary Receipt ( ...

The Nasdaq is one of the top three most-followed stock market indices in the United States, comprising over 2,500 stocks.

In this essay, we will explore the symptoms of ATTR-CM and the five treatment options available for the heart condition.

PASADENA, CA, USA I 10 2025 I Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the global licensing and collaboration agreement ...

Cut off any part of this worm's body and it will regrow. This is the spectacular yet mysterious regenerative ability of ...